LWLei Wang

Lei Wang

*This is an algorithmically generated author record based on publicly available information.

Lei Wang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    On-column thiol protection strategy to control charge and stability of ThiomAb

    by Kai Ni, Leo (Lei) Wang, Alan Shupe, Timothy Cooney, Joshua Dai, Christopher Barton, George Parks, Christina Alves

    Background: Cysteine-engineered monoclonal antibodies (mAbs), or ThiomAb, enable site-specific conjugation and form the basis of several next-generation antibody-drug conjugates (ADCs). However, the presence of intentionally unpaired cysteine residues introduces reactive free thiols that pose challenges for manufacturing consistency, including variable capping by cysteine/glutathione or uncapped free thiol during cell culture. This increases the charge heterogeneity of protein and may compromise stability due to increased risk of oxidation, disulfide scrambling, or aggregation. Methods: To address these risks, we developed an on-column capping strategy, in which the antibody is immobilized on chromatography resin during the capture step and subjected to selective thiol masking under optimized redox conditions. This in-process approach allows for early and efficient stabilization of engineered thiol sites prior to polishing and formulation. High-throughput condition screening and analytical techniques—including mass spectrometry and charge variant profiling—were employed to fine-tune buffer conditions and understand on-column redox chemistry. Results: The optimized thiol protection conditions substantially reduce the population of free thiols, resulting in more consistent charge profiles and improved stability during downstream processing and storage. Conclusion: This strategy offers a scalable and platform-adaptable solution for enhancing the manufacturability and alternative control strategy of ThiomAb intermediates used in site-specific ADC processes.

  • Open Access

    Elucidation of Proteoforms of Chinese Hamster Ovary (CHO) Phospholipase B‐Like 2 (PLBL2) Captured From a Monoclonal Antibody

    by Michael E. Dolan, Lei (Leo) Wang, Alexander Tedeschi, Yan Wang, Christopher Barton, Sheldon F. Oppenheim, Zhaohui Sunny Zhou

    Removing host cell proteins (HCPs) during biotherapeutic manufacturing is essential to ensure patient safety and supply continuity. Yet, this goal remains exceptionally challenging for some HCP species. For example, phospholipase B‐like‐2 (PLBL2) from Chinese hamster ovary (CHO) cells plagues process engineers by evading typical purification strategies. Separation challenges for CHO PLBL2 and other HCPs are due in large part to a dearth of detailed biochemical characterization for HCPs, such as their proteoforms or variants. Herein, we present as a case study the elucidation of proteoforms of PLBL2, which was endogenously expressed in CHO alongside pembrolizumab (a monoclonal IgG4 antibody) and inadvertently co‐purified following a typical downstream process. Using site‐specifically modified polyclonal anti‐CHO PLBL2 antibodies immobilized onto a solid support, CHO PLBL2 was captured from pembrolizumab, enriched, and recovered, enabling deep characterization by mass spectrometry and other techniques. These analyses revealed a detailed understanding of CHO PLBL2's proteoforms, including charge variants, N‐linked and O‐linked glycosylation, phosphorylation, and cleavage to afford multiple molecular weight isoforms. To the best of our knowledge, this is the first published, deep characterization of a challenging CHO HCP. Armed with a greater understanding of the impurities that plague purification processes, we can design new, targeted strategies to ensure their removal and safeguard both patient safety and biotherapeutic supplies. While our work centered on CHO PLBL2, our antibody immobilization, affinity enrichment, and characterization approach should be broadly applicable to enable the examination of innumerable challenging HCPs from modalities across the increasingly diverse bioprocessing landscape.


  • Open Access

    First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region

    by Michael E Dolan, Amissi Sadiki, Leo (Lei) Wang, Yan Wang, Christopher Barton, Sheldon F Oppenheim, Zhaohui Sunny Zhou

    Despite their triumph in treating human diseases, antibody therapies for animals have gained momentum more slowly. However, the first approvals of animal antibodies for osteoarthritic pain in cats and dogs may herald the dawn of a new era. For example, goats are vital to economies around the world for their milk, meat, and hide products. It is therefore imperative to develop therapies to safeguard goats—with antibodies at the forefront. Goat antibodies will be crucial in the development of therapeutic antibodies, for example, as tracers to study antibody distribution in vivo, reagents to develop other therapeutic antibodies, and therapeutic agents themselves (e.g., antibody-drug conjugates). Hamstringing this effort is a still-burgeoning understanding of goat antibodies and their derivatization. Historically, goat antibody conjugates were generated through stochastic chemical modifications, producing numerous attachment sites and modification ratios, thereby deleteriously impacting antigen binding. Site-specific methods exist but often require substantial engineering and have not been demonstrated with goat antibodies. Nevertheless, we present herein a novel method to site-specifically conjugate native goat antibodies: chemo-enzymatic remodeling of the native Fc N-glycan introduces a reactive azide handle, after which click chemistry with strained alkyne partners affords homogeneous conjugates labeled only on the Fc domain. This process is robust, and resulting conjugates retain their antigen binding and specificity. To our knowledge, our report is the first for site-specific conjugation of native goat antibodies. Furthermore, our approach should be applicable to other animal antibodies—even with limited structural information—with similar success.


  • Open Access

    Data from A Fluorescence In situ Hybridization Screen for E26 Transformation–Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer

    by Bo Han, Rohit Mehra, Saravana M. Dhanasekaran, Jindan Yu, Anjana Menon, Robert J. Lonigro, Xiaosong Wang, Yusong Gong, Lei Wang, Sunita Shankar, et al.

    Recurrent gene fusions involving E26 transformation–specific (ETS) transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in 40% to 70% of prostate cancers. Here, we used a comprehensive fluorescence in situ hybridization (FISH) split probe strategy interrogating all 27 ETS family members and their five known 5′ fusion partners in a cohort of 110 clinically localized prostate cancer patients. Gene rearrangements were only identified in ETS genes that were previously implicated in prostate cancer gene fusions including ERG, ETV1, and ETV4 (43%, 5%, and 5%, respectively), suggesting that a substantial fraction of prostate cancers (estimated at 30–60%) cannot be attributed to an ETS gene fusion. Among the known 5′ gene fusion partners, TMPRSS2 was rearranged in 47% of cases followed by SLC45A3, HNRPA2B1, and C15ORF21 in 2%, 1%, and 1% of cases, respectively. Based on this comprehensive FISH screen, we have made four noteworthy observations. First, by screening the entire ETS transcription factor family for rearrangements, we found that a large fraction of prostate cancers (44%) cannot be ascribed to an ETS gene fusion, an observation which will stimulate research into identifying recurrent non-ETS aberrations in prostate cancers. Second, we identified SLC45A3 as a novel 5′ fusion partner of ERG; previously, TMPRSS2 was the only described 5′ partner of ERG. Third, we identified two prostate-specific, androgen-induced genes, FLJ35294 and CANT1, as 5′ partners to ETV1 and ETV4. Fourth, we identified a ubiquitously expressed, androgen-insensitive gene, DDX5, fused in frame with ETV4, leading to the expression of a DDX5-ETV4 fusion protein. [Cancer Res 2008;68(18):7629–37]

  • Open Access

    Data from A Fluorescence In situ Hybridization Screen for E26 Transformation–Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer

    by Bo Han, Rohit Mehra, Saravana M. Dhanasekaran, Jindan Yu, Anjana Menon, Robert J. Lonigro, Xiaosong Wang, Yusong Gong, Lei Wang, Sunita Shankar, et al.

    Recurrent gene fusions involving E26 transformation–specific (ETS) transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in 40% to 70% of prostate cancers. Here, we used a comprehensive fluorescence in situ hybridization (FISH) split probe strategy interrogating all 27 ETS family members and their five known 5′ fusion partners in a cohort of 110 clinically localized prostate cancer patients. Gene rearrangements were only identified in ETS genes that were previously implicated in prostate cancer gene fusions including ERG, ETV1, and ETV4 (43%, 5%, and 5%, respectively), suggesting that a substantial fraction of prostate cancers (estimated at 30–60%) cannot be attributed to an ETS gene fusion. Among the known 5′ gene fusion partners, TMPRSS2 was rearranged in 47% of cases followed by SLC45A3, HNRPA2B1, and C15ORF21 in 2%, 1%, and 1% of cases, respectively. Based on this comprehensive FISH screen, we have made four noteworthy observations. First, by screening the entire ETS transcription factor family for rearrangements, we found that a large fraction of prostate cancers (44%) cannot be ascribed to an ETS gene fusion, an observation which will stimulate research into identifying recurrent non-ETS aberrations in prostate cancers. Second, we identified SLC45A3 as a novel 5′ fusion partner of ERG; previously, TMPRSS2 was the only described 5′ partner of ERG. Third, we identified two prostate-specific, androgen-induced genes, FLJ35294 and CANT1, as 5′ partners to ETV1 and ETV4. Fourth, we identified a ubiquitously expressed, androgen-insensitive gene, DDX5, fused in frame with ETV4, leading to the expression of a DDX5-ETV4 fusion protein. [Cancer Res 2008;68(18):7629–37]

  • Open Access

    Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips

    by Chuntao Wu, Beiyuan Hu, Lei Wang, Xia Wu, Haitao Gu, Hanguang Dong, Jiuliang Yan, Zihao Qi, Qi Zhang, Huan Chen, et al.